(Q34514715)

2 August 2017

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta (English)

1 reference

2 August 2017

0 references

0 references

Bibiana Bielekova

1

1 reference

2 August 2017

Nancy Richert

2

1 reference

2 August 2017

Thomas Howard

3

1 reference

2 August 2017

Gregg Blevins

4

1 reference

2 August 2017

Silva Markovic-Plese

5

1 reference

2 August 2017

Jennifer McCartin

6

1 reference

2 August 2017

Joseph A Frank

7

1 reference

2 August 2017

Jens Würfel

8

1 reference

2 August 2017

Joan Ohayon

9

1 reference

2 August 2017

Thomas A Waldmann

10

1 reference

2 August 2017

Henry F McFarland

11

1 reference

2 August 2017

Roland Martin

12

1 reference

2 August 2017

language of work or name

English

0 references

publication date

25 May 2004

1 reference

2 August 2017

4

1 reference

Proceedings of the National Academy of Sciences of the United States of America

inferred from page(s)

published in

1 reference

2 August 2017

101

1 reference

2 August 2017

8705-8708

1 reference

2 August 2017

23

1 reference

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=423259

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=423259

Clinical scales for multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=423259

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=423259

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=423259

Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=423259

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.

7 July 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0402653101

Correspondence of closest gradient voxels--a robust registration algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0402653101

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0402653101

Prospective study on the relationship between infections and multiple sclerosis exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0402653101

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0402653101

A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0402653101

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

21 January 2018

1 reference

12 December 2020

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

1 reference

12 December 2020

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

12 December 2020

The use of antibodies against the IL-2 receptor in transplantation

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.0402653101

1 reference

2 August 2017

0 references

1 reference

2 August 2017

1 reference